{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=azacitidine&page=31", "query": { "intervention": "azacitidine", "page": 31 }, "page_size": 10 }, "pagination": { "page": 31, "page_size": 10, "total_count": 695, "total_pages": 70, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=azacitidine&page=32&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=azacitidine&page=30&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T07:54:29.427Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02319369", "title": "Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myelogenous Leukemia", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Milademetan", "type": "DRUG" }, { "name": "AZA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2014-11-25", "completion_date": "2020-08-21", "has_results": true, "last_update_posted_date": "2021-10-11", "last_synced_at": "2026-10-26T07:54:29.427Z", "location_count": 5, "location_summary": "Duarte, California • San Francisco, California • Fairway, Kansas + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Fairway", "state": "Kansas" }, { "city": "Buffalo", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02319369" }, { "nct_id": "NCT02071927", "title": "Study of the Glutaminase Inhibitor CB-839 in Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia (AML)", "Acute Lymphocytic Leukemia (ALL)" ], "interventions": [ { "name": "CB-839", "type": "DRUG" }, { "name": "CB-Aza", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Calithera Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2014-03", "completion_date": "2016-12", "has_results": false, "last_update_posted_date": "2017-02-09", "last_synced_at": "2026-10-26T07:54:29.427Z", "location_count": 5, "location_summary": "Denver, Colorado • Chicago, Illinois • Buffalo, New York + 2 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Buffalo", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02071927" }, { "nct_id": "NCT03182894", "title": "Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Epacadostat (INCB024360) in Combination with Pembrolizumab (MK-3475) and Azacitidine (VIDAZA)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "James J Lee", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2018-09-30", "completion_date": "2020-07-30", "has_results": false, "last_update_posted_date": "2018-08-28", "last_synced_at": "2026-10-26T07:54:29.427Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03182894" }, { "nct_id": "NCT03161223", "title": "Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma, T-Cell" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Pralatrexate", "type": "DRUG" }, { "name": "Romidepsin", "type": "DRUG" }, { "name": "5-Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 148, "start_date": "2018-05-30", "completion_date": "2023-02", "has_results": false, "last_update_posted_date": "2022-03-31", "last_synced_at": "2026-10-26T07:54:29.427Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03161223" }, { "nct_id": "NCT01983969", "title": "Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Cancers", "Lymphoma" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Caphosol", "type": "OTHER" }, { "name": "Glutamine", "type": "DRUG" }, { "name": "Pyridoxine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "15 Years to 65 Years" }, "enrollment_count": 61, "start_date": "2013-11-07", "completion_date": "2017-11-22", "has_results": true, "last_update_posted_date": "2020-01-27", "last_synced_at": "2026-10-26T07:54:29.427Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01983969" }, { "nct_id": "NCT00000623", "title": "Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Anemia, Cooley's", "Beta-Thalassemia", "Hematologic Diseases", "Thalassemia", "Osteoporosis", "Iron Overload", "Hypertension, Pulmonary" ], "interventions": [ { "name": "Deferoxamine", "type": "DRUG" }, { "name": "Deferiprone", "type": "DRUG" }, { "name": "Arginine", "type": "DRUG" }, { "name": "Sildenafil", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Carelon Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "75 Years", "sex": "ALL", "summary": "1 Year to 75 Years" }, "enrollment_count": 1000, "start_date": "2000-07", "completion_date": "2006-07", "has_results": false, "last_update_posted_date": "2014-03-04", "last_synced_at": "2026-10-26T07:54:29.427Z", "location_count": 4, "location_summary": "Oakland, California • Boston, Massachusetts • New York, New York + 1 more", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000623" }, { "nct_id": "NCT02264873", "title": "Phase I, Dose Escalation Study of Decitabine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, Lymphoblastic, Acute", "Leukemia, Myeloid Acute", "Hematopoetic Myelodysplasia" ], "interventions": [ { "name": "Decitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 3, "start_date": "2014-10", "completion_date": "2018-09-18", "has_results": false, "last_update_posted_date": "2018-10-15", "last_synced_at": "2026-10-26T07:54:29.427Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02264873" }, { "nct_id": "NCT03397173", "title": "TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndromes", "Myeloproliferative Neoplasm", "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Ascorbic acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2018-03-16", "completion_date": "2021-01-21", "has_results": false, "last_update_posted_date": "2021-08-11", "last_synced_at": "2026-10-26T07:54:29.427Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03397173" }, { "nct_id": "NCT06930651", "title": "A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myeloid Malignancies" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" }, { "name": "TGFBR2 KO CAR27/IL-15 NK cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 42, "start_date": "2025-09-03", "completion_date": "2030-05-01", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-10-26T07:54:29.427Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06930651" }, { "nct_id": "NCT05379166", "title": "Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Secondary Myelodysplastic Syndrome", "Therapy-Related Myelodysplastic Syndrome" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Uma Borate", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2022-06-23", "completion_date": "2026-12-15", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-10-26T07:54:29.427Z", "location_count": 3, "location_summary": "Columbus, Ohio • Portland, Oregon • Dallas, Texas", "locations": [ { "city": "Columbus", "state": "Ohio" }, { "city": "Portland", "state": "Oregon" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05379166" } ] }